stages of OCEANiC trial

What is OCEANiC?

The TOGA OCEANIC study follows on from the ADAURA study which showed a significant improvement in DFS and OS compared to placebo.

OCEANiC will provide free access to a TKI inhibitor and aims to evaluate if chemotherapy can be omitted in patients with EGFR mutant NSCLC who are at low risk of recurrence following complete surgical resection.

How do I refer a patient?

Potential patients need ctDNA collected within 28 days of surgical resection. Additional information and participating sites can be found here.
If you have a potential participant, please contact your nearest active trial site.

Recruiting hospitals:

  • Peter MacCallum Cancer Centre – Melbourne
  • St Vincent’s Hospital (Melbourne) Ltd – Fitzroy
  • Austin Health – Austin Hospital – Heidelberg
  • Monash Medical Centre – Clayton campus – Clayton
  • The Chris O’Brien Lifehouse – Camperdown
  • GenesisCare – St Leonards – St Leonards
  • Liverpool Hospital – Liverpool
  • The Prince Charles Hospital – Chermside
  • Fiona Stanley Hospital – Murdoch

If you have any questions about the OCEANiC study, please do not hesitate to contact the OCEANiC team at or find out here